-+ 0.00%
-+ 0.00%
-+ 0.00%
Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease
Share
Listen to the news

Grifols ((MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today presents new real-world evidence (RWE) data from the AMBAR® (Alzheimer Management by Albumin Replacement) program, contributing to the ongoing research evaluating the use of therapeutic plasma exchange (TPE) with albumin replacement in patients with mild cognitive impairment and mild to moderate Alzheimer’s disease.

The new data come from a real-world observational study conducted at Ace Alzheimer Center Barcelona that included 71 patients followed for 18 months. Patients received up to 21 TPE sessions with albumin replacement, performed on an outpatient basis and exclusively using peripheral venous access.

The cognitive outcomes suggest that the overall Mini-Mental State Examination (MMSE) score, one of the most widely used scales for assessing cognitive function, declined by 3.1 points over 18 months, equivalent to 2.5 points per year. This represents a lower rate of decline than the approximately 3.3 points per year reported in natural history studies of Alzheimer’s disease.*

Overall, the results support the feasibility and favorable safety profile of outpatient TPE using peripheral venous access.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending